WallStSmart

Addex Therapeutics Ltd (ADXN)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 329% more annual revenue ($742,000 vs $172,860). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ADXN earns a higher WallStSmart Score of 30/100 (F).

ADXN

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 1/9Altman Z: -80.94

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADXN3 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
950.0%10/10

Revenue surging 950.0% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ADXN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.42M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ADXN

The strongest argument for ADXN centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 950.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ADXN

The primary concerns for ADXN are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ADXN profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

ADXN carries more volatility with a beta of 1.98 — expect wider price swings.

ADXN is growing revenue faster at 950.0% — sustainability is the question.

ADXN generates stronger free cash flow (-608,401), providing more financial flexibility.

Bottom Line

ADXN scores higher overall (30/100 vs 24/100) and 950.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Addex Therapeutics Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Addex Therapeutics Ltd, a developing-stage biopharmaceutical company, discovers, develops and markets small molecule pharmaceuticals for central nervous system (CNS) disorders in Switzerland. The company is headquartered in Geneva, Switzerland.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?